Skip to main content
. 2023 Feb 20;7(3):e0063. doi: 10.1097/HC9.0000000000000063

FIGURE 2.

FIGURE 2

Incidence of liver adverse events. (A) Incidence of treatment-related hepatotoxicity according to the adverse event type. (B) Incidence of immune-mediated hepatotoxicity according to the adverse event type. (C) Incidence of treatment-related hepatotoxicity according to the treatment regimen. (D) Incidence of treatment-related all-grade hepatotoxicity according to the treatment regimen. (E), Incidence of treatment-related grade 3–5 hepatotoxicity according to the treatment regimen. (F) Immune-mediated all-grade hepatotoxicity according to the treatment regimen. (G) Immune-mediated grade 3–5 hepatotoxicity according to the treatment regimen. Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Chemo, chemotherapy; CTLA-4, cytotoxic T-lymphocyte antigen 4 inhibitor; GGT, gamma-glutamyl transferase; ICIs, immune checkpoint inhibitors; PD-1, programmed cell death 1 inhibitor; PD-L1, programmed cell death ligand 1 inhibitor; TTD, targeted therapy drug.